The drug, a grape-flavored solution called maralixibat, is approved for children age 1 and older. Foster City, California-based Mirum will market its new product under the name “Livmarli.” Alagille ...

Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only ...

Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli. Mirum has multiple potential catalysts on the way in 2026. In several important ...

Mirum Pharmaceuticals Inc. plans to “move rapidly toward regulatory filings” to expand use of IBAT inhibitor Livmarli (maralixibat) into progressive familial intrahepatic cholestasis (PFIC), President ...

Like two crafty boxers, Albireo and Mirum Pharmaceuticals are bobbing and weaving, answering punches with counterpunches, in their battle to treat a trio of pediatric liver diseases with their ...

Although progressive familial intrahepatic cholestasis (PFIC) tends to draw more hoopla in the race, and Mirum Pharmaceuticals Inc. looks due to beat Albireo Pharma Inc. to market in Alagille syndrome ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical ...

Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year. A recent acquisition could also negatively affect the bottom line.